Compare CSX Corporation (CSX) vs Neurocrine Biosciences Inc (NBIX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
CSX Corporation vs Neurocrine Biosciences Inc — how do they compare? CSX Corporation trades at $47.29 (market cap $87.70B), while Neurocrine Biosciences Inc trades at $142.25 (market cap $14.36B). The key difference: CSX Corporation is far larger — about 6.1× Neurocrine Biosciences Inc's market cap, and CSX Corporation pays a 1.18% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold CSX Corporation for 55 Days and Neurocrine Biosciences Inc for 23 Days on average.
| CSX | NBIX | |
|---|---|---|
Market Cap | $87.70B | $14.36B |
Volume | 6,980,781 | 1,237,180 |
Sector | Industrials | Health |
52-Week High | $53.21 | $185.50 |
52-Week Low | $33.68 | $123.10 |
Typical Hold Time | 55 Days | 23 Days |
Enterprise Value | $105.66B | $14.37B |
Dividend Yield | 1.18% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CSX trades at $47.28, up 0.99% today, with a bullish technical signal and strong institutional interest. The railroad operator shows solid profitability with 22.2% net margins and 24.4% ROE, though revenue has declined from $14.9B in 2022 to $14.1B in 2025. Analysts maintain a buy consensus with a $51 target, representing 8% upside. Recent news highlights upcoming Q3 earnings and institutional acquisitions.
CSX offers moderate upside potential with strong operational metrics offset by revenue pressures. Key opportunities include pricing power in freight rail and dividend growth, while risks involve economic sensitivity and competitive threats. The stock's premium valuation requires sustained execution to justify current levels.
Neurocrine Biosciences (NBIX) trades at $141.69, down 1.24% on the day, with a bearish technical signal from moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and consistent earnings beats, including a significant Q2 2026 beat. Recent news highlights pipeline advancements and executive appointments, while analyst sentiment remains overwhelmingly positive.
The outlook for NBIX is supported by robust fundamentals and strong analyst buy ratings, but near-term price action is challenged by technical bearishness. Key opportunities include product diversification and pipeline growth, while risks involve execution of expansion plans and potential pricing pressures on key products like INGREZZA.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About CSX Corporation
Operating in the Eastern United States, Class I railroad CSX generated revenue near $12.5 billion in 2021. On its more than 21,000 miles of track, CSX hauls shipments of coal (13% of consolidated revenue), chemicals (22%), intermodal containers (16%), automotive cargo (9%), and a diverse mix of other bulk and industrial merchandise.
Read more on CSX →About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →
